Well, it is true that we know that a high-risk recurrence during or shortly after BCG is equal to radical cystectomy. But, however, we have several approved therapies for CIS BCG unresponsive in the U.S., no therapies for papillary only, or no therapies for CIS BCG unresponsive in other countries, and radical cystectomy still remains the standard of care for these patients...
Well, it is true that we know that a high-risk recurrence during or shortly after BCG is equal to radical cystectomy. But, however, we have several approved therapies for CIS BCG unresponsive in the U.S., no therapies for papillary only, or no therapies for CIS BCG unresponsive in other countries, and radical cystectomy still remains the standard of care for these patients. It is also true that if we, with the combination in the upfront line for BCG-naive, high-risk non-muscle-invasive cancer, if we are achieving less high-grade recurrences and we are avoiding high-grade recurrences, there will be less patients who should be submitted to a radical cystectomy or to one of these new therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
